Levosimendan Kalceks

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer presented as an intravenous solution for intravenous use. It enhances cardiac contractility and promotes vasodilation, making it indicated for the treatment of acute decompensated heart failure in adult patients who require rapid hemodynamic support.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, and specialty clinics worldwide under strict quality‑assurance standards. Our distribution network ensures timely delivery, regulatory compliance, and support for pharmacovigilance across multiple regions.

Levosimendan is used in the management of acute heart‑related conditions where improved contractility and vasodilation are needed. - Acute decompensated heart failure: increases cardiac output and reduces filling pressures. - Low cardiac output syndrome: enhances myocardial contractility without raising intracellular calcium. - Post‑cardiac surgery low output: supports hemodynamics during early postoperative recovery.

Levosimendan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea or vomiting: gastrointestinal discomfort. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked blood pressure reduction requiring intervention. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Anaphylactic reactions: rare allergic responses. - Pulmonary edema: fluid accumulation in lungs.

Levosimendan requires careful monitoring and specific precautions before and during therapy. - Blood pressure monitoring: watch for hypotension, especially during initial infusion. - Cardiac rhythm assessment: observe for arrhythmias, particularly in patients with existing conduction disorders. - Avoid in severe hypotension: contraindicated when systolic pressure is markedly low. - Caution in renal impairment: adjust therapy based on renal function. - Use with care in hepatic dysfunction: metabolized in liver, monitor liver enzymes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Concurrent inotropes (e.g., dopamine): risk of excessive cardiac stimulation. - Potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Beta‑blockers: can blunt the intended inotropic effect.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - ACE inhibitors or ARBs: watch for additive blood‑pressure lowering. - Calcium channel blockers: may affect vascular response and heart rate.